Original article: Case-Serie of 4 COVID-19 patients hospitalized in an intensive care unit in a hospital institution in Barranquilla, Colombia
PDF (Español)


Coronavirus; COVID-19; SARS-CoV-2; acute kidney injury; multi-system failure; chloroquine; azithromycin; ICU.

How to Cite

Iglesias Pertuz S, Aroca-Martinez G, Vélez-Verbel M, Cadena Osorio A, Cadena-Bonfanti A, Correa-Monterrosa M, Lemus Castro J, Brochado L, Armesto W, Camargo Vasquez T, Martínez Bula E, Turizo Turizo E, Avendaño Echavez LG, Hernández-Agudelo S, Peña Vargas W, Riascos W, Palmera J, Sierra A, Varón Suárez F, Gómez Giraldo L, González-Torres H, Navarro Quiroz E, Vásquez Obeso E, Ángel Depine S, Ospino Herrera D. Original article: Case-Serie of 4 COVID-19 patients hospitalized in an intensive care unit in a hospital institution in Barranquilla, Colombia. Rev. Colomb. Nefrol. [Internet]. 2020 Apr. 13 [cited 2024 Jul. 16];7(Supl.2). Available from: https://revistanefrologia.org/index.php/rcn/article/view/420


To present a COVID-19 case series with clinical admission criteria to Intensive Care Unit. Patients information was obtained from medical records, and daily clinical evaluation whereas diagnosis was carried out through paraclinical studies in blood, urine, PCR and diagnostic images in 4 patients with different comorbidities and epidemiological link for the development of COVID-19. All four cases were managed with chloroquine 300 mg orally every 12 hours and azithromycin orally every 24 hours for 5 days without complications or associated toxicity.The case 1 developed multiple organ failure, including acute kidney injury with an ICU stay of 4 days before his death, while cases 2, 3 and 4 had a favorable evolution and were discharged fromthe ICU. Rapid multicenter studies are required to scientifically guide a better diagnostic and management approach, in the context of a disease with a clinical-epidemiological behavior that must be studied in depth and will probably take many lives. In addition, due to the absence of sufficiently rapid tests, the use of a classification based on the severity of radiological lesions called CO-RADS (Covid-19 Imaging Reporting and Data System) could be of great importance to install available pharmacological treatments early and early mechanical respiratory support. 

PDF (Español)


World Health Organization. Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. https://www.who.int/ dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020.

Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirusfrom a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814-1820. Available from: https://doi.org/10.1056/NEJMoa1211721

Wilde AH de, Snijder EJ, Kikkert M, Van MJ. Host Factors in Coronavirus Replication. Curr Top Microbiol Immunol. 2017;37:35. Available from: https://doi.org/10.1007/82

Müller MA, Corman VM, Jores J, et al. Mers coronavirus neutralizing antibodies in camels, eastern Africa, 1983-1997. Emerg Infect Dis. 2014;20(12):2093-2095. Available from: https://doi.org/10.3201/eid2012.141026

Organización Mundial de la Salud. Nuevo coronavirus- China.

Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. Tob Induc Dis. 2020;18(March):20. Available from: https://doi.org/10.18332/tid/119324

Han R, Huang L, Jiang H, Dong J, Peng H, Zhang D. Early Clinical and CT Manifestations of Coronavirus Disease 2019 (COVID-19) Pneumonia. Am J Roentgenol. 2020;(1):1-6. Available from: https://doi.org/10.2214/ajr.20.22961

Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - J Am Med Assoc. 2020;323(11):1061-1069. Available from: https://doi.org/10.1001/jama.2020.1585

Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. Jama. 2020:1-8. Available from: https://doi.org/10.1001/jama.2020.5394

Grasselli G, Pesenti A, Cecconi M. Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy. JAMA - J Am Med Assoc. 2020.

Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA - J Am Med Assoc. 2020;2019:3-6. Available from: https://doi.org/10.1001/jama.2020.2648

Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. Jama. 2020;2019:2019-2020. Available from: https://doi.org/10.1001/jama.2020. 4683 13. Salud instituto nacional de. Coronavirus (COVID - 2019) En Colombia. 2020.

Smithuis F, Smithuis R. 32 cases of suspected COVID-19 Imaging findings and follow up. Radiology Assistant.

World Health Organization (WHO). Coronavirus Disease 2019 (COVID-19) Situation Report – 82. 2020.

Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in Critically Ill Patients in the Seattle Region — Case Series. N Engl J Med. March 2020:NEJMoa2004500. Available from: https://doi.org/10.1056/NEJMoa2004500

Liu Y, Yan L-M, Wan L, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis. 2020;2019(20):2019-2020. Available from: https://doi.org/10.1016/S1473-3099(20)30232-2

Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. Available from: https://doi.org/10.1016/s0140-6736(20)30566-3

Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N Engl J Med. 2020:1199-1207. Available from: https://doi.org/10.1056/nejmoa2001316

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. Available from: https://doi.org/10.1016/S0140-6736(20)30183-5

Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. Available from: https://doi.org/10.1016/S0140-6736(20)30566-3

Murthy S, Gomersall CD, Fowler RA. Care for Critically Ill Patients with COVID-19. JAMA - J Am Med Assoc. 2020:1-2. Available from: https://doi.org/10.1001/jama.2020.3633

Wang T, Du Z, Zhu F, et al. Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet. 2020;395(10228):e52. Available from: https://doi.org/10.1016/S0140-6736(20)30558-4

Panitchote A, Mehkri O, Hasting A, et al. Factors associated with acute kidney injury in acute respiratory distress syndrome. Ann Intensive Care. 2019;9(1). Available from: https://doi.org/:10.1186/s13613-019-0552-5

Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;(March). Available from: https://doi.org/10.1016/j.kint.2020.03.005

Volunteers A-2019-nCoV, Li Z, Wu M, et al. Caution on Kidney Dysfunctions of 2019-nCoV Patients. medRxiv.

:2020.02.08.20021212. Available from: https://doi.org/10.1101/2020.02.08.20021212

Bai HX, Hsieh B, Xiong Z, et al. Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT. Radiology. 2020:200823. Available from: https://doi.org/10.1148/radiol.2020 200823

Simpson S, Kay FU, Abbara S, et al. Radiological Society of North America Expert Consensus Statement on Reporting Chest CT Findings Related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA. Radiol Cardiothorac Imaging. 2020;2(2): e200152. Available from: https://doi.org/10.1148/ryct.2020200152

Colson P, Rolain J-M, LagierJ-C, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020:105932. Available from: https://doi.org/10.1016/j.ijantimicag.2020.105932

Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Main point?: Hydroxychloroquine was found to be more potent than chloroquine at inhibiting SARS-CoV-2 in vit. Clin Infect Dis. 2020;2:1-25.

Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial. Int J Antimicrob Agents. 2020:105949. Available from: https://doi.org/10.1016/j.ijantimicag. 2020.105949

Chan JFW, Yanfeng Yao A, Yeung M-L, et al. Treatment with lopinavir/ritonavir or interferon-?1b improves outcome of MERS-CoV infection in a non-human primate model of common marmoset. J Infect Dis. 2020;212(12).

No national or foreign publication may partially or totally reproduce or translate Revista Colombiana de Nefrología articles or abstracts without prior written permission from the journal’s Editorial Board.




Download data is not yet available.